nodes	percent_of_prediction	percent_of_DWPC	metapath
Regadenoson—Cladribine—NR5A1—ovarian cancer	0.0196	0.704	CrCbGaD
Regadenoson—Adenosine triphosphate—AKT1—ovarian cancer	0.00703	0.252	CrCbGaD
Regadenoson—Hypersensitivity—Melphalan—ovarian cancer	0.00197	0.00202	CcSEcCtD
Regadenoson—Asthenia—Topotecan—ovarian cancer	0.00195	0.00201	CcSEcCtD
Regadenoson—Vomiting—Chlorambucil—ovarian cancer	0.00195	0.002	CcSEcCtD
Regadenoson—Mental disorder—Paclitaxel—ovarian cancer	0.00193	0.00199	CcSEcCtD
Regadenoson—Erythema—Paclitaxel—ovarian cancer	0.00192	0.00198	CcSEcCtD
Regadenoson—Feeling abnormal—Vinorelbine—ovarian cancer	0.00192	0.00198	CcSEcCtD
Regadenoson—Renal impairment—Epirubicin—ovarian cancer	0.00192	0.00197	CcSEcCtD
Regadenoson—Asthenia—Melphalan—ovarian cancer	0.00191	0.00197	CcSEcCtD
Regadenoson—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.00191	0.00196	CcSEcCtD
Regadenoson—Dysgeusia—Paclitaxel—ovarian cancer	0.00188	0.00194	CcSEcCtD
Regadenoson—Eye pain—Doxorubicin—ovarian cancer	0.00187	0.00192	CcSEcCtD
Regadenoson—Diarrhoea—Topotecan—ovarian cancer	0.00186	0.00192	CcSEcCtD
Regadenoson—Hypoaesthesia—Docetaxel—ovarian cancer	0.00186	0.00191	CcSEcCtD
Regadenoson—Cerebrovascular accident—Epirubicin—ovarian cancer	0.00186	0.00191	CcSEcCtD
Regadenoson—Urticaria—Vinorelbine—ovarian cancer	0.00185	0.0019	CcSEcCtD
Regadenoson—Abdominal pain—Vinorelbine—ovarian cancer	0.00184	0.0019	CcSEcCtD
Regadenoson—Connective tissue disorder—Docetaxel—ovarian cancer	0.00184	0.00189	CcSEcCtD
Regadenoson—Diarrhoea—Melphalan—ovarian cancer	0.00183	0.00188	CcSEcCtD
Regadenoson—Pain in extremity—Epirubicin—ovarian cancer	0.00182	0.00188	CcSEcCtD
Regadenoson—Nausea—Chlorambucil—ovarian cancer	0.00182	0.00187	CcSEcCtD
Regadenoson—Vision blurred—Paclitaxel—ovarian cancer	0.00181	0.00186	CcSEcCtD
Regadenoson—Dizziness—Topotecan—ovarian cancer	0.0018	0.00185	CcSEcCtD
Regadenoson—Tremor—Paclitaxel—ovarian cancer	0.0018	0.00185	CcSEcCtD
Regadenoson—Ill-defined disorder—Paclitaxel—ovarian cancer	0.00178	0.00183	CcSEcCtD
Regadenoson—Renal impairment—Doxorubicin—ovarian cancer	0.00177	0.00182	CcSEcCtD
Regadenoson—Angioedema—Paclitaxel—ovarian cancer	0.00176	0.00181	CcSEcCtD
Regadenoson—Eye disorder—Docetaxel—ovarian cancer	0.00175	0.0018	CcSEcCtD
Regadenoson—Flushing—Docetaxel—ovarian cancer	0.00174	0.00179	CcSEcCtD
Regadenoson—Cardiac disorder—Docetaxel—ovarian cancer	0.00174	0.00179	CcSEcCtD
Regadenoson—Cardiac arrest—Epirubicin—ovarian cancer	0.00173	0.00178	CcSEcCtD
Regadenoson—Vomiting—Topotecan—ovarian cancer	0.00173	0.00178	CcSEcCtD
Regadenoson—Malaise—Paclitaxel—ovarian cancer	0.00173	0.00178	CcSEcCtD
Regadenoson—Syncope—Paclitaxel—ovarian cancer	0.00172	0.00177	CcSEcCtD
Regadenoson—Cerebrovascular accident—Doxorubicin—ovarian cancer	0.00172	0.00177	CcSEcCtD
Regadenoson—Rash—Topotecan—ovarian cancer	0.00172	0.00177	CcSEcCtD
Regadenoson—Hypersensitivity—Vinorelbine—ovarian cancer	0.00172	0.00177	CcSEcCtD
Regadenoson—Dermatitis—Topotecan—ovarian cancer	0.00172	0.00177	CcSEcCtD
Regadenoson—Headache—Topotecan—ovarian cancer	0.00171	0.00176	CcSEcCtD
Regadenoson—Palpitations—Paclitaxel—ovarian cancer	0.0017	0.00175	CcSEcCtD
Regadenoson—Angiopathy—Docetaxel—ovarian cancer	0.0017	0.00175	CcSEcCtD
Regadenoson—Vomiting—Melphalan—ovarian cancer	0.0017	0.00175	CcSEcCtD
Regadenoson—Immune system disorder—Docetaxel—ovarian cancer	0.00169	0.00174	CcSEcCtD
Regadenoson—Loss of consciousness—Paclitaxel—ovarian cancer	0.00169	0.00174	CcSEcCtD
Regadenoson—Pain in extremity—Doxorubicin—ovarian cancer	0.00169	0.00174	CcSEcCtD
Regadenoson—Mediastinal disorder—Docetaxel—ovarian cancer	0.00169	0.00173	CcSEcCtD
Regadenoson—Rash—Melphalan—ovarian cancer	0.00168	0.00173	CcSEcCtD
Regadenoson—Dermatitis—Melphalan—ovarian cancer	0.00168	0.00173	CcSEcCtD
Regadenoson—Cough—Paclitaxel—ovarian cancer	0.00168	0.00172	CcSEcCtD
Regadenoson—Asthenia—Vinorelbine—ovarian cancer	0.00167	0.00172	CcSEcCtD
Regadenoson—Convulsion—Paclitaxel—ovarian cancer	0.00166	0.00171	CcSEcCtD
Regadenoson—Hypertension—Paclitaxel—ovarian cancer	0.00166	0.00171	CcSEcCtD
Regadenoson—Mental disorder—Docetaxel—ovarian cancer	0.00164	0.00169	CcSEcCtD
Regadenoson—Myalgia—Paclitaxel—ovarian cancer	0.00164	0.00168	CcSEcCtD
Regadenoson—Chest pain—Paclitaxel—ovarian cancer	0.00164	0.00168	CcSEcCtD
Regadenoson—Arthralgia—Paclitaxel—ovarian cancer	0.00164	0.00168	CcSEcCtD
Regadenoson—Anxiety—Paclitaxel—ovarian cancer	0.00163	0.00168	CcSEcCtD
Regadenoson—Erythema—Docetaxel—ovarian cancer	0.00163	0.00167	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.00162	0.00167	CcSEcCtD
Regadenoson—Nausea—Topotecan—ovarian cancer	0.00162	0.00166	CcSEcCtD
Regadenoson—Discomfort—Paclitaxel—ovarian cancer	0.00162	0.00166	CcSEcCtD
Regadenoson—Cardiac arrest—Doxorubicin—ovarian cancer	0.0016	0.00165	CcSEcCtD
Regadenoson—Diarrhoea—Vinorelbine—ovarian cancer	0.00159	0.00164	CcSEcCtD
Regadenoson—Dysgeusia—Docetaxel—ovarian cancer	0.00159	0.00164	CcSEcCtD
Regadenoson—Abdominal distension—Epirubicin—ovarian cancer	0.00159	0.00163	CcSEcCtD
Regadenoson—Nausea—Melphalan—ovarian cancer	0.00158	0.00163	CcSEcCtD
Regadenoson—Asthma—Epirubicin—ovarian cancer	0.00158	0.00162	CcSEcCtD
Regadenoson—Anaphylactic shock—Paclitaxel—ovarian cancer	0.00157	0.00161	CcSEcCtD
Regadenoson—Shock—Paclitaxel—ovarian cancer	0.00154	0.00159	CcSEcCtD
Regadenoson—Dizziness—Vinorelbine—ovarian cancer	0.00154	0.00159	CcSEcCtD
Regadenoson—Nervous system disorder—Paclitaxel—ovarian cancer	0.00154	0.00158	CcSEcCtD
Regadenoson—Angina pectoris—Epirubicin—ovarian cancer	0.00154	0.00158	CcSEcCtD
Regadenoson—Tachycardia—Paclitaxel—ovarian cancer	0.00153	0.00157	CcSEcCtD
Regadenoson—Skin disorder—Paclitaxel—ovarian cancer	0.00152	0.00157	CcSEcCtD
Regadenoson—Hyperhidrosis—Paclitaxel—ovarian cancer	0.00152	0.00156	CcSEcCtD
Regadenoson—Vomiting—Vinorelbine—ovarian cancer	0.00148	0.00152	CcSEcCtD
Regadenoson—Rash—Vinorelbine—ovarian cancer	0.00147	0.00151	CcSEcCtD
Regadenoson—Dermatitis—Vinorelbine—ovarian cancer	0.00147	0.00151	CcSEcCtD
Regadenoson—Abdominal distension—Doxorubicin—ovarian cancer	0.00147	0.00151	CcSEcCtD
Regadenoson—Hypotension—Paclitaxel—ovarian cancer	0.00147	0.00151	CcSEcCtD
Regadenoson—Headache—Vinorelbine—ovarian cancer	0.00146	0.0015	CcSEcCtD
Regadenoson—Syncope—Docetaxel—ovarian cancer	0.00146	0.0015	CcSEcCtD
Regadenoson—Asthma—Doxorubicin—ovarian cancer	0.00146	0.0015	CcSEcCtD
Regadenoson—Palpitations—Docetaxel—ovarian cancer	0.00144	0.00148	CcSEcCtD
Regadenoson—Loss of consciousness—Docetaxel—ovarian cancer	0.00143	0.00147	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.00143	0.00147	CcSEcCtD
Regadenoson—Cough—Docetaxel—ovarian cancer	0.00142	0.00146	CcSEcCtD
Regadenoson—Angina pectoris—Doxorubicin—ovarian cancer	0.00142	0.00146	CcSEcCtD
Regadenoson—Insomnia—Paclitaxel—ovarian cancer	0.00142	0.00146	CcSEcCtD
Regadenoson—Convulsion—Docetaxel—ovarian cancer	0.00141	0.00145	CcSEcCtD
Regadenoson—Paraesthesia—Paclitaxel—ovarian cancer	0.00141	0.00145	CcSEcCtD
Regadenoson—Hypertension—Docetaxel—ovarian cancer	0.00141	0.00145	CcSEcCtD
Regadenoson—Dyspnoea—Paclitaxel—ovarian cancer	0.0014	0.00144	CcSEcCtD
Regadenoson—Somnolence—Paclitaxel—ovarian cancer	0.00139	0.00143	CcSEcCtD
Regadenoson—Arthralgia—Docetaxel—ovarian cancer	0.00139	0.00143	CcSEcCtD
Regadenoson—Myalgia—Docetaxel—ovarian cancer	0.00139	0.00143	CcSEcCtD
Regadenoson—Chest pain—Docetaxel—ovarian cancer	0.00139	0.00143	CcSEcCtD
Regadenoson—Nausea—Vinorelbine—ovarian cancer	0.00138	0.00142	CcSEcCtD
Regadenoson—Renal failure—Epirubicin—ovarian cancer	0.00138	0.00142	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.00138	0.00142	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.00135	0.00139	CcSEcCtD
Regadenoson—Pain—Paclitaxel—ovarian cancer	0.00134	0.00138	CcSEcCtD
Regadenoson—Anaphylactic shock—Docetaxel—ovarian cancer	0.00133	0.00137	CcSEcCtD
Regadenoson—Shock—Docetaxel—ovarian cancer	0.00131	0.00134	CcSEcCtD
Regadenoson—Nervous system disorder—Docetaxel—ovarian cancer	0.0013	0.00134	CcSEcCtD
Regadenoson—Tachycardia—Docetaxel—ovarian cancer	0.0013	0.00133	CcSEcCtD
Regadenoson—Feeling abnormal—Paclitaxel—ovarian cancer	0.00129	0.00133	CcSEcCtD
Regadenoson—Skin disorder—Docetaxel—ovarian cancer	0.00129	0.00133	CcSEcCtD
Regadenoson—Bradycardia—Epirubicin—ovarian cancer	0.00128	0.00132	CcSEcCtD
Regadenoson—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.00128	0.00132	CcSEcCtD
Regadenoson—Renal failure—Doxorubicin—ovarian cancer	0.00128	0.00131	CcSEcCtD
Regadenoson—Hypoaesthesia—Epirubicin—ovarian cancer	0.00126	0.00129	CcSEcCtD
Regadenoson—Urticaria—Paclitaxel—ovarian cancer	0.00125	0.00128	CcSEcCtD
Regadenoson—Hypotension—Docetaxel—ovarian cancer	0.00124	0.00128	CcSEcCtD
Regadenoson—Connective tissue disorder—Epirubicin—ovarian cancer	0.00124	0.00128	CcSEcCtD
Regadenoson—Abdominal pain—Paclitaxel—ovarian cancer	0.00124	0.00127	CcSEcCtD
Regadenoson—Adenosine triphosphate—ABCB1—ovarian cancer	0.00123	0.0441	CrCbGaD
Regadenoson—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.00121	0.00125	CcSEcCtD
Regadenoson—Insomnia—Docetaxel—ovarian cancer	0.0012	0.00124	CcSEcCtD
Regadenoson—Paraesthesia—Docetaxel—ovarian cancer	0.00119	0.00123	CcSEcCtD
Regadenoson—Bradycardia—Doxorubicin—ovarian cancer	0.00119	0.00122	CcSEcCtD
Regadenoson—Dyspnoea—Docetaxel—ovarian cancer	0.00118	0.00122	CcSEcCtD
Regadenoson—Somnolence—Docetaxel—ovarian cancer	0.00118	0.00122	CcSEcCtD
Regadenoson—Eye disorder—Epirubicin—ovarian cancer	0.00118	0.00121	CcSEcCtD
Regadenoson—Tinnitus—Epirubicin—ovarian cancer	0.00118	0.00121	CcSEcCtD
Regadenoson—Flushing—Epirubicin—ovarian cancer	0.00117	0.0012	CcSEcCtD
Regadenoson—Cardiac disorder—Epirubicin—ovarian cancer	0.00117	0.0012	CcSEcCtD
Regadenoson—Hypoaesthesia—Doxorubicin—ovarian cancer	0.00116	0.00119	CcSEcCtD
Regadenoson—Hypersensitivity—Paclitaxel—ovarian cancer	0.00116	0.00119	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.00115	0.00118	CcSEcCtD
Regadenoson—Connective tissue disorder—Doxorubicin—ovarian cancer	0.00115	0.00118	CcSEcCtD
Regadenoson—Angiopathy—Epirubicin—ovarian cancer	0.00114	0.00118	CcSEcCtD
Regadenoson—Immune system disorder—Epirubicin—ovarian cancer	0.00114	0.00117	CcSEcCtD
Regadenoson—Mediastinal disorder—Epirubicin—ovarian cancer	0.00114	0.00117	CcSEcCtD
Regadenoson—Pain—Docetaxel—ovarian cancer	0.00114	0.00117	CcSEcCtD
Regadenoson—Asthenia—Paclitaxel—ovarian cancer	0.00112	0.00116	CcSEcCtD
Regadenoson—Mental disorder—Epirubicin—ovarian cancer	0.00111	0.00114	CcSEcCtD
Regadenoson—Erythema—Epirubicin—ovarian cancer	0.0011	0.00113	CcSEcCtD
Regadenoson—Feeling abnormal—Docetaxel—ovarian cancer	0.0011	0.00113	CcSEcCtD
Regadenoson—Eye disorder—Doxorubicin—ovarian cancer	0.00109	0.00112	CcSEcCtD
Regadenoson—Tinnitus—Doxorubicin—ovarian cancer	0.00109	0.00112	CcSEcCtD
Regadenoson—Gastrointestinal pain—Docetaxel—ovarian cancer	0.00109	0.00112	CcSEcCtD
Regadenoson—Cardiac disorder—Doxorubicin—ovarian cancer	0.00108	0.00111	CcSEcCtD
Regadenoson—Flushing—Doxorubicin—ovarian cancer	0.00108	0.00111	CcSEcCtD
Regadenoson—Dysgeusia—Epirubicin—ovarian cancer	0.00108	0.00111	CcSEcCtD
Regadenoson—Diarrhoea—Paclitaxel—ovarian cancer	0.00107	0.0011	CcSEcCtD
Regadenoson—Angiopathy—Doxorubicin—ovarian cancer	0.00106	0.00109	CcSEcCtD
Regadenoson—Immune system disorder—Doxorubicin—ovarian cancer	0.00105	0.00108	CcSEcCtD
Regadenoson—Mediastinal disorder—Doxorubicin—ovarian cancer	0.00105	0.00108	CcSEcCtD
Regadenoson—Abdominal pain—Docetaxel—ovarian cancer	0.00105	0.00108	CcSEcCtD
Regadenoson—Dizziness—Paclitaxel—ovarian cancer	0.00104	0.00107	CcSEcCtD
Regadenoson—Vision blurred—Epirubicin—ovarian cancer	0.00104	0.00106	CcSEcCtD
Regadenoson—Mental disorder—Doxorubicin—ovarian cancer	0.00102	0.00105	CcSEcCtD
Regadenoson—Ill-defined disorder—Epirubicin—ovarian cancer	0.00102	0.00105	CcSEcCtD
Regadenoson—Erythema—Doxorubicin—ovarian cancer	0.00102	0.00105	CcSEcCtD
Regadenoson—Vomiting—Paclitaxel—ovarian cancer	0.000997	0.00103	CcSEcCtD
Regadenoson—Dysgeusia—Doxorubicin—ovarian cancer	0.000995	0.00102	CcSEcCtD
Regadenoson—Malaise—Epirubicin—ovarian cancer	0.00099	0.00102	CcSEcCtD
Regadenoson—Rash—Paclitaxel—ovarian cancer	0.000989	0.00102	CcSEcCtD
Regadenoson—Dermatitis—Paclitaxel—ovarian cancer	0.000988	0.00102	CcSEcCtD
Regadenoson—Syncope—Epirubicin—ovarian cancer	0.000985	0.00101	CcSEcCtD
Regadenoson—Headache—Paclitaxel—ovarian cancer	0.000982	0.00101	CcSEcCtD
Regadenoson—Hypersensitivity—Docetaxel—ovarian cancer	0.000979	0.00101	CcSEcCtD
Regadenoson—Palpitations—Epirubicin—ovarian cancer	0.000971	0.000998	CcSEcCtD
Regadenoson—Loss of consciousness—Epirubicin—ovarian cancer	0.000965	0.000993	CcSEcCtD
Regadenoson—Cough—Epirubicin—ovarian cancer	0.000958	0.000986	CcSEcCtD
Regadenoson—Vision blurred—Doxorubicin—ovarian cancer	0.000958	0.000985	CcSEcCtD
Regadenoson—Asthenia—Docetaxel—ovarian cancer	0.000953	0.000981	CcSEcCtD
Regadenoson—Convulsion—Epirubicin—ovarian cancer	0.000952	0.000979	CcSEcCtD
Regadenoson—Hypertension—Epirubicin—ovarian cancer	0.000948	0.000975	CcSEcCtD
Regadenoson—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000943	0.00097	CcSEcCtD
Regadenoson—Arthralgia—Epirubicin—ovarian cancer	0.000935	0.000962	CcSEcCtD
Regadenoson—Myalgia—Epirubicin—ovarian cancer	0.000935	0.000962	CcSEcCtD
Regadenoson—Chest pain—Epirubicin—ovarian cancer	0.000935	0.000962	CcSEcCtD
Regadenoson—Anxiety—Epirubicin—ovarian cancer	0.000932	0.000959	CcSEcCtD
Regadenoson—Nausea—Paclitaxel—ovarian cancer	0.000931	0.000958	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000929	0.000955	CcSEcCtD
Regadenoson—Discomfort—Epirubicin—ovarian cancer	0.000924	0.00095	CcSEcCtD
Regadenoson—Malaise—Doxorubicin—ovarian cancer	0.000916	0.000943	CcSEcCtD
Regadenoson—Syncope—Doxorubicin—ovarian cancer	0.000911	0.000937	CcSEcCtD
Regadenoson—Diarrhoea—Docetaxel—ovarian cancer	0.000909	0.000935	CcSEcCtD
Regadenoson—Palpitations—Doxorubicin—ovarian cancer	0.000898	0.000924	CcSEcCtD
Regadenoson—Anaphylactic shock—Epirubicin—ovarian cancer	0.000896	0.000922	CcSEcCtD
Regadenoson—Loss of consciousness—Doxorubicin—ovarian cancer	0.000893	0.000919	CcSEcCtD
Regadenoson—Cough—Doxorubicin—ovarian cancer	0.000887	0.000912	CcSEcCtD
Regadenoson—Shock—Epirubicin—ovarian cancer	0.000882	0.000907	CcSEcCtD
Regadenoson—Convulsion—Doxorubicin—ovarian cancer	0.00088	0.000906	CcSEcCtD
Regadenoson—Nervous system disorder—Epirubicin—ovarian cancer	0.000879	0.000904	CcSEcCtD
Regadenoson—Dizziness—Docetaxel—ovarian cancer	0.000879	0.000904	CcSEcCtD
Regadenoson—Hypertension—Doxorubicin—ovarian cancer	0.000877	0.000903	CcSEcCtD
Regadenoson—Tachycardia—Epirubicin—ovarian cancer	0.000875	0.0009	CcSEcCtD
Regadenoson—Skin disorder—Epirubicin—ovarian cancer	0.000871	0.000896	CcSEcCtD
Regadenoson—Hyperhidrosis—Epirubicin—ovarian cancer	0.000867	0.000891	CcSEcCtD
Regadenoson—Arthralgia—Doxorubicin—ovarian cancer	0.000865	0.00089	CcSEcCtD
Regadenoson—Chest pain—Doxorubicin—ovarian cancer	0.000865	0.00089	CcSEcCtD
Regadenoson—Myalgia—Doxorubicin—ovarian cancer	0.000865	0.00089	CcSEcCtD
Regadenoson—Anxiety—Doxorubicin—ovarian cancer	0.000862	0.000887	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000859	0.000884	CcSEcCtD
Regadenoson—Discomfort—Doxorubicin—ovarian cancer	0.000855	0.000879	CcSEcCtD
Regadenoson—Vomiting—Docetaxel—ovarian cancer	0.000845	0.000869	CcSEcCtD
Regadenoson—Rash—Docetaxel—ovarian cancer	0.000838	0.000862	CcSEcCtD
Regadenoson—Hypotension—Epirubicin—ovarian cancer	0.000838	0.000862	CcSEcCtD
Regadenoson—Dermatitis—Docetaxel—ovarian cancer	0.000837	0.000861	CcSEcCtD
Regadenoson—Headache—Docetaxel—ovarian cancer	0.000833	0.000856	CcSEcCtD
Regadenoson—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000829	0.000853	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000817	0.00084	CcSEcCtD
Regadenoson—Shock—Doxorubicin—ovarian cancer	0.000816	0.000839	CcSEcCtD
Regadenoson—Nervous system disorder—Doxorubicin—ovarian cancer	0.000813	0.000837	CcSEcCtD
Regadenoson—Insomnia—Epirubicin—ovarian cancer	0.000811	0.000834	CcSEcCtD
Regadenoson—Tachycardia—Doxorubicin—ovarian cancer	0.000809	0.000833	CcSEcCtD
Regadenoson—Skin disorder—Doxorubicin—ovarian cancer	0.000806	0.000829	CcSEcCtD
Regadenoson—Paraesthesia—Epirubicin—ovarian cancer	0.000805	0.000828	CcSEcCtD
Regadenoson—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000802	0.000825	CcSEcCtD
Regadenoson—Dyspnoea—Epirubicin—ovarian cancer	0.000799	0.000822	CcSEcCtD
Regadenoson—Somnolence—Epirubicin—ovarian cancer	0.000797	0.00082	CcSEcCtD
Regadenoson—Nausea—Docetaxel—ovarian cancer	0.000789	0.000812	CcSEcCtD
Regadenoson—Hypotension—Doxorubicin—ovarian cancer	0.000775	0.000797	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000774	0.000796	CcSEcCtD
Regadenoson—Pain—Epirubicin—ovarian cancer	0.000766	0.000788	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000756	0.000777	CcSEcCtD
Regadenoson—Insomnia—Doxorubicin—ovarian cancer	0.00075	0.000772	CcSEcCtD
Regadenoson—Paraesthesia—Doxorubicin—ovarian cancer	0.000745	0.000766	CcSEcCtD
Regadenoson—Dyspnoea—Doxorubicin—ovarian cancer	0.000739	0.000761	CcSEcCtD
Regadenoson—Feeling abnormal—Epirubicin—ovarian cancer	0.000739	0.00076	CcSEcCtD
Regadenoson—Somnolence—Doxorubicin—ovarian cancer	0.000737	0.000758	CcSEcCtD
Regadenoson—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000733	0.000754	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000716	0.000737	CcSEcCtD
Regadenoson—Urticaria—Epirubicin—ovarian cancer	0.000712	0.000732	CcSEcCtD
Regadenoson—Pain—Doxorubicin—ovarian cancer	0.000709	0.00073	CcSEcCtD
Regadenoson—Abdominal pain—Epirubicin—ovarian cancer	0.000709	0.000729	CcSEcCtD
Regadenoson—Feeling abnormal—Doxorubicin—ovarian cancer	0.000683	0.000703	CcSEcCtD
Regadenoson—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000678	0.000698	CcSEcCtD
Regadenoson—Hypersensitivity—Epirubicin—ovarian cancer	0.00066	0.000679	CcSEcCtD
Regadenoson—Urticaria—Doxorubicin—ovarian cancer	0.000659	0.000678	CcSEcCtD
Regadenoson—Abdominal pain—Doxorubicin—ovarian cancer	0.000656	0.000674	CcSEcCtD
Regadenoson—Asthenia—Epirubicin—ovarian cancer	0.000643	0.000662	CcSEcCtD
Regadenoson—Diarrhoea—Epirubicin—ovarian cancer	0.000613	0.000631	CcSEcCtD
Regadenoson—Hypersensitivity—Doxorubicin—ovarian cancer	0.000611	0.000629	CcSEcCtD
Regadenoson—Asthenia—Doxorubicin—ovarian cancer	0.000595	0.000612	CcSEcCtD
Regadenoson—Dizziness—Epirubicin—ovarian cancer	0.000593	0.00061	CcSEcCtD
Regadenoson—Vomiting—Epirubicin—ovarian cancer	0.00057	0.000586	CcSEcCtD
Regadenoson—Diarrhoea—Doxorubicin—ovarian cancer	0.000567	0.000584	CcSEcCtD
Regadenoson—Rash—Epirubicin—ovarian cancer	0.000565	0.000581	CcSEcCtD
Regadenoson—Dermatitis—Epirubicin—ovarian cancer	0.000565	0.000581	CcSEcCtD
Regadenoson—Headache—Epirubicin—ovarian cancer	0.000562	0.000578	CcSEcCtD
Regadenoson—Dizziness—Doxorubicin—ovarian cancer	0.000548	0.000564	CcSEcCtD
Regadenoson—Nausea—Epirubicin—ovarian cancer	0.000532	0.000548	CcSEcCtD
Regadenoson—Vomiting—Doxorubicin—ovarian cancer	0.000527	0.000542	CcSEcCtD
Regadenoson—Rash—Doxorubicin—ovarian cancer	0.000523	0.000538	CcSEcCtD
Regadenoson—Dermatitis—Doxorubicin—ovarian cancer	0.000522	0.000537	CcSEcCtD
Regadenoson—Headache—Doxorubicin—ovarian cancer	0.00052	0.000534	CcSEcCtD
Regadenoson—Nausea—Doxorubicin—ovarian cancer	0.000493	0.000507	CcSEcCtD
